AB

ABION Inc.

Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.

203400 | KO

Overview

Corporate Details

ISIN(s):
KR7203400007
LEI:
Country:
South Korea
Address:
서울특별시 구로구 디지털로 242 한화비즈메트로1차 242915호, 서울특별시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

ABION Inc. is a clinical-stage biopharmaceutical company pioneering the development of innovative, first-in-class and best-in-class therapeutics. The company's research and development efforts are primarily focused on oncology and viral infectious diseases. Its lead oncology candidate, ABN401, is a targeted c-Met tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC) that has demonstrated a superior safety profile in clinical trials. The pipeline also includes ABN501, a novel Claudin-3 targeting monoclonal antibody for various cancers. In its infectious disease program, ABION is developing ABN101, a second-generation Interferon-β inhaler as a broad-spectrum anti-viral therapy for respiratory infections. The company aims to address significant unmet medical needs through internationally recognized clinical processes for eventual global commercialization.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 126.5 KB
2025-09-16 00:00
Related Party Transaction
[기재정정]타법인주식및출자증권처분결정
Korean 12.3 KB
2025-09-12 00:00
Capital/Financing Update
전환사채(해외전환사채포함)발행후만기전사채취득
Korean 9.9 KB
2025-09-12 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 126.5 KB
2025-09-12 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유무상증자결정)
Korean 52.8 KB
2025-09-12 00:00
Registration Form
[기재정정]증권신고서(지분증권) (2025.11)
Korean 3.5 MB
2025-09-09 00:00
Capital/Financing Update
단기차입금증가결정
Korean 9.6 KB
2025-08-29 00:00
Share Issue/Capital Change
주권매매거래정지 (무상증자)
Korean 4.7 KB
2025-08-29 00:00
Share Issue/Capital Change
주요사항보고서(유무상증자결정)
Korean 40.0 KB
2025-08-29 00:00
Registration Form
증권신고서(지분증권) (2025.10)
Korean 2.5 MB
2025-08-22 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 11.6 KB
2025-08-22 00:00
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 9.9 KB
2025-08-22 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 130.0 KB
2025-08-20 00:00
Major Shareholding Notification
최대주주변경을수반하는주식담보제공계약해제ㆍ취소등
Korean 15.4 KB
2025-08-14 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 1.9 MB

Automate Your Workflow. Get a real-time feed of all ABION Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ABION Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ABION Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.